CD8A and neoplasm: Consistent with this study, our data demonstrated that combination treatment with UDCA and an anti-PD-1 notably increased antitumor CD8+ T cell responses, decreased the Treg cells among TILs, and enhanced tumor-specific immune memory, thus greatly improving the antitumor effects.